Medimmune Limited

Humabs Biomed Sa

Medlmmune Limited

Christine Tkaczyk

Bret Sellman

Lei Hua

Davide Corti

Partha S Chowdhury

Melissa Marie Damschroder

Brett R Sellman

Andrea Minola

Qun Du

Peter Pavlik

Chew-shun Chang

Rebecca Buonpane

Melissa Hamilton

Martin Borrok, Iii

Reena Varkey

Vaheh Oganesyan

Li Peng

Jamese Johnson Hilliard

Taylor Cohen

Chew-Shun Chang

The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to aclumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating ainfection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds toalpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.

Antibody directed againstclumping factor A (ClfA)

The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventinginfections.

Antibodies directed againstleukotoxins

Antibodies and antigen binding fragments thereof directed against() surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treatingusing the antibodies and antigen binding fragments thereof are also provided.

[object Object]

The present disclosure is directed to anti-antibody combinations including combinations of antibodies that bind toalpha toxin (AT) protein, clumping factor A protein (ClfA), and/or at least one leukotoxin protein. Methods of treating and preventing infections comprising administering the antibody combinations are also provided herein.

Combinations of anti-antibodies

Antibody directed againstclumping factor a (ClfA)

The present invention provides for methods of preventing and/or treating-associated bacteremia and sepsis, and methods for preventing and/or treating-associated pneumonia in immunocompromised patients using anti-alpha-toxin (anti-AT) antibodies. Also provided are methods of reducingbacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducingbacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity ofassociated pneumonia in an immunocompromised mammalian subject.

Methods of treating-associated diseases

Antibodies tosurface determinants

Herein provided are compositions, methods of manufacture and methods of use pertaining to anti-alpha toxin antibodies and fragments.

Growing community of inventors

Gaithersburg, MD, United States of America

Christine Tkaczyk